Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | pNGVL4a-hCRT-E6E7L2 + TA-CIN |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TA-CIN | HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN | TA-CIN is a cancer vaccine comprising a fusion protein of HPV16 L2, E6, and E7, which potentially increases immune response to HPV-related tumors (PMID: 19095032, PMID: 15131030). | ||
| pNGVL4a-hCRT-E6E7L2 | pNGVL4a hCRT E6E7L2|pNGVL4a-CRT-E6E7L2|pNGVL4aCRTE6E7L2|pNGVL4a CRT E6E7L2 | pNGVL4a-hCRT-E6E7L2 is a DNA vaccine that encodes calreticulin linked to the HPV-16 E6, E7, and L2 epitopes, which potentially induces CD8-positive T-cell specific immune response against tumors expressing E6 and E7, and reduces the growth of HPV-related tumors (PMID: 24594273). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|